Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

Séverine Vermeire, Stefan Schreiber(University Hospital Schleswig-Holstein), Robert Petryka(NZOZ Centrum Alergologii), Tanja Kuehbacher(Asklepios), Xavier Hébuterne(Centre Hospitalier Universitaire de Nice), Xavier Roblin(Centre Hospitalier Universitaire de Saint-Étienne), Maria Kłopocka(Collegium Medicum in Bydgoszcz), Adrian Goldiș(West University of Timişoara), Maria Wiśniewska‐Jarosińska(Medical University of Lodz), Andrey Baranovsky(St Petersburg University), Róbert Sike(Szent János Kórház), Kremena Stoyanova, Chantal Tasset(Galapagos (Belgium)), Annegret Van der Aa(Galapagos (Belgium)), Pille Harrison(Galapagos (Belgium))
The Lancet
December 14, 2016
Cited by 436

Abstract


Related Papers

No related papers found

Powered by citation graph analysis